登录 | 注册    关注公众号  
微信公众号
搜索
 > 【ICOS】

ICOS信息

英文名称:Inducible T-cell costimulator
中文名称:诱导T细胞共刺激分子
靶点别称:Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
上市药物数量:0
临床药物数量:6
最高研发阶段:临床二期

ICOS 分子别名

ICOS,CD278,AILIM,Inducible T-cell costimulator

ICOS 分子背景

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS 前沿进展

ICOS临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Anti-ICOS (Bristol Myers Squibb) BMS-986226 临床一期 肿瘤 详情
Izuralimab XmAb-23104; XmAb-104 Xencor 详情
MEDI-570 临床一期 日本烟草(香港)有限公司 滤泡中心淋巴瘤, T-细胞淋巴瘤, 非霍奇金淋巴瘤, 蕈样真菌病 详情
Acazicolcept ALPN-101 临床二期 Alpine Immune Sciences, 艾伯维 移植物抗宿主病, 自身免疫疾病, 系统性红斑狼疮, X-连锁淋巴增生症, 炎性疾病 详情
Alomfilimab KY-1044 临床二期 Kymab 头颈部鳞状细胞癌, 肾细胞癌, 食道癌, 胃癌, 三阴性乳腺肿瘤, 肿瘤, 胰腺癌, 黑色素瘤, 肝细胞癌, 非小细胞肺癌, 宫颈癌, 转移癌 详情
Vopratelimab JTX-2011 临床二期 Jounce Therapeutics 肿瘤, 非小细胞肺癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定